Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jill Lacy

Showing results (31-40 of 59) with videos related to

Pageof 6
Sort By:
Journal of the National Comprehensive Cancer Network : JNCCN|May 7, 2017
Identification of Targetable <i>ALK</i> Rearrangements in Pancreatic Ductal AdenocarcinomaAatur D Singhi, Siraj M Ali, Jill Lacy, et al.
Plos One|September 29, 2021
Renalase is a novel tissue and serological biomarker in pancreatic ductal adenocarcinomaYasheen Gao, Melinda Wang, Xiaojia Guo, et al.
Cancer|December 22, 2020
A phase 1b expansion study of TAS-102 with oxaliplatin for refractory metastatic colorectal cancerMichael Cecchini, Jeremy S Kortmansky, Can Cui, et al.
Cancer Research Communications|June 30, 2023
Quantitative DNA Repair Biomarkers and Immune Profiling for Temozolomide and Olaparib in Metastatic Colorectal CancerMichael Cecchini, Janie Y Zhang, Wei Wei, et al.
British Journal of Cancer|March 30, 2016
Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancerStacey M Stein, Edward S James, Yanhong Deng, et al.
Journal of the National Cancer Institute|May 22, 2024
Combining antivascular endothelial growth factor and anti-epidermal growth factor receptor antibodies: randomized phase II study of irinotecan and cetuximab with/without ramucirumab in second-line colorectal cancer (ECOG-ACRIN E7208)Howard S Hochster, Paul Catalano, Michelle Weitz, et al.
The Oncologist|February 25, 2026
Atezolizumab and Motixafortide, Cobimetinib or Simlukafusp Alfa in Pretreated Advanced Pancreatic Cancer: Phase I/IIb MORPHEUS-PDAC Umbrella StudyGulam A Manji, Vincent Chung, Do-Youn Oh, et al.
Clinical and Translational Radiation Oncology|January 4, 2021
Margin negative resection and pathologic downstaging with multiagent chemotherapy with or without radiotherapy in patients with localized pancreas cancer: A national cancer database analysisJoseph A Miccio, Wesley J Talcott, Timil Patel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2019
Phase IB/II Randomized Study of FOLFIRINOX Plus Pegylated Recombinant Human Hyaluronidase Versus FOLFIRINOX Alone in Patients With Metastatic Pancreatic Adenocarcinoma: SWOG S1313Ramesh K Ramanathan, Shannon L McDonough, Philip A Philip, et al.
JAMA Network Open|January 5, 2023
Effect of a MUC5AC Antibody (NPC-1C) Administered With Second-Line Gemcitabine and Nab-Paclitaxel on the Survival of Patients With Advanced Pancreatic Ductal Adenocarcinoma: A Randomized Clinical TrialBrandon M Huffman, Atrayee Basu Mallick, Nora K Horick, et al.
Pageof 6

Showing results (31-40 of 59) with videos related to

Sort By:
Pageof 6
Journal of the National Comprehensive Cancer Network : JNCCN|May 7, 2017
Identification of Targetable <i>ALK</i> Rearrangements in Pancreatic Ductal AdenocarcinomaAatur D Singhi, Siraj M Ali, Jill Lacy, et al.
Plos One|September 29, 2021
Renalase is a novel tissue and serological biomarker in pancreatic ductal adenocarcinomaYasheen Gao, Melinda Wang, Xiaojia Guo, et al.
Cancer|December 22, 2020
A phase 1b expansion study of TAS-102 with oxaliplatin for refractory metastatic colorectal cancerMichael Cecchini, Jeremy S Kortmansky, Can Cui, et al.
Cancer Research Communications|June 30, 2023
Quantitative DNA Repair Biomarkers and Immune Profiling for Temozolomide and Olaparib in Metastatic Colorectal CancerMichael Cecchini, Janie Y Zhang, Wei Wei, et al.
British Journal of Cancer|March 30, 2016
Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancerStacey M Stein, Edward S James, Yanhong Deng, et al.
Journal of the National Cancer Institute|May 22, 2024
Combining antivascular endothelial growth factor and anti-epidermal growth factor receptor antibodies: randomized phase II study of irinotecan and cetuximab with/without ramucirumab in second-line colorectal cancer (ECOG-ACRIN E7208)Howard S Hochster, Paul Catalano, Michelle Weitz, et al.
The Oncologist|February 25, 2026
Atezolizumab and Motixafortide, Cobimetinib or Simlukafusp Alfa in Pretreated Advanced Pancreatic Cancer: Phase I/IIb MORPHEUS-PDAC Umbrella StudyGulam A Manji, Vincent Chung, Do-Youn Oh, et al.
Clinical and Translational Radiation Oncology|January 4, 2021
Margin negative resection and pathologic downstaging with multiagent chemotherapy with or without radiotherapy in patients with localized pancreas cancer: A national cancer database analysisJoseph A Miccio, Wesley J Talcott, Timil Patel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2019
Phase IB/II Randomized Study of FOLFIRINOX Plus Pegylated Recombinant Human Hyaluronidase Versus FOLFIRINOX Alone in Patients With Metastatic Pancreatic Adenocarcinoma: SWOG S1313Ramesh K Ramanathan, Shannon L McDonough, Philip A Philip, et al.
JAMA Network Open|January 5, 2023
Effect of a MUC5AC Antibody (NPC-1C) Administered With Second-Line Gemcitabine and Nab-Paclitaxel on the Survival of Patients With Advanced Pancreatic Ductal Adenocarcinoma: A Randomized Clinical TrialBrandon M Huffman, Atrayee Basu Mallick, Nora K Horick, et al.
Pageof 6